Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This letter to the editor describes a case of acquired progressive kinking of the hair in a Korean female adolescent, but no new research findings are reported.

This research found that topical minoxidil may promote hair regrowth in alopecia areata by stimulating hair follicle epithelium and suppressing certain immune responses, with potential contributions from its vasodilatory effects.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This case study from Ukraine describes a 5-year-old Akita dog diagnosed with sebaceous adenitis, presenting with pruritus, alopecia, and inflammation; treatment over 30 days led to complete restoration of affected areas, implicating potential heritability in Akitas.

This discussion highlights that alopecia areata incognita is challenging to diagnose and treat, with systemic corticosteroids potentially leading to remission when local treatments fail.

This study provides a comprehensive overview of actinic keratosis, highlighting its potential to progress to squamous cell carcinoma and noting that routine treatment poses a significant burden on healthcare providers.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

In this study, Korean red ginseng combined with corticosteroid injections showed potential efficacy in treating alopecia areata over 12 weeks, suggesting it as a useful complementary treatment.

This source reports that recent research highlights the effectiveness and tolerability of oral JAK inhibitors for treating moderate to severe alopecia areata, although further placebo-controlled studies are needed to confirm their long-term safety and efficacy.

This study identified serum androsterone as a robust biomarker for monitoring response to AKR1C3 inhibitor treatment in women and found that a 4-week administration of aldo-keto reductase 1C3 inhibitors did not impact ovarian function.

This study observed that inflammatory AIGA is associated with sweat duct inflammation and sweat coil atrophy, while non-inflammatory AIGA involves only sweat coil atrophy, suggesting distinct pathological features between the two.

This article reviews acute disseminated encephalomyelitis, a neurological condition with demyelination of the central nervous system, and reports no new clinical findings; diagnosis is made by exclusion.

This study found that integrin-linked kinase is crucial for various epidermal functions, including differentiation and barrier formation, and also plays a previously unreported role in melanocyte development and function.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This study developed the Alopecia Areata Children's Quality of Life Index (AAcQLI) to assess quality of life in children with alopecia areata, demonstrating good reliability and validity in initial tests.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This study found that manipulating AKR1D1 expression in human liver cells effectively regulates glucocorticoid clearance and receptor activation, highlighting its role in liver-specific steroid hormone regulation.

ITK inhibitors may effectively treat alopecia areata.

JAK inhibitors may reduce depression risk in alopecia areata patients.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.

This source presents an expert consensus framework for determining which Australian patients with alopecia areata should receive subsidized JAK inhibitor therapy, emphasizing the need for future research including patient perspectives to enhance criteria, ensure fair treatment access, and evaluate real-world outcomes.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This study found that dermoscopy is valuable for diagnosing facial actinic keratosis in Chinese patients, with specific patterns like red pseudonetwork and follicular plugs suggesting its utility in differential diagnosis.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This study found that both androgenetic alopecia and alopecia areata showed significantly increased DKK-1 expression, potentially implicating it in the pathogenesis and as a treatment target for these conditions.